Abstract Search

ea0098c1 | Clinical – Chemo/SSA/Biologics | NANETS2023

Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients living with metastatic neuroendocrine tumors

Krishnan Tharani , Safro Maria , Moreira Furlanetto Daniel , Gill Sharlene , Paulo Solar Vasconcelos Joao , Stuart Heather C. , Martineau Patrick , Loree Jonathan M.

Background: Octreotide LAR is a long-acting somatostatin analogue used in the management of metastatic neuroendocrine tumors (NETs), with antiproliferative and symptom control effects. It requires intramuscular (IM) injection. Missed IM injections can cause subcutaneous nodules (SCNs) on radiologic images. We reviewed the rates of SCNs in a real-world cohort of NETs receiving octreotide LAR and explored treatment outcomes.Methods: Patients with gastroint...

1 shares

Endocrine Abstracts

Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients living with metastatic neuroendocrine tumors

BiosciAbstracts